LIH383 (TFA)

LIH383 TFA is an agonist of ACKR3 (CXCR7) (EC50=0.61 nM) . LIH383 TFA efficiently induces the recruitment of β-arrestin to ACKR3 but does not trigger typical G protein signaling[1].

12352209

CXCR

GPCR/G Protein; Immunology/Inflammation

COVID-19-immunoregulation

Inflammation/Immunology; Neurological Disease

99.83

O=C(NCC(NCC(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCSC)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N)=O)=O)=O)=O)=O)=O)=O)[C@H](CC2=CC=CC=C2)N.O=C(O)C(F)(F)F.[x]

C45H72N16O8S.xC2HF3O2

997.22 (free base)

[1]Meyrath M, et al. The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides. Nat Commun. 2020 Jun 19;11 (1) :3033.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10333A/LIH383-TFA-SDS-MedChemExpress.pdf

Peptides

No Development Reported